A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA
Mad in America
AUGUST 14, 2024
L ykos Therapeutics experienced a double blow this week, with the FDA’s rejection of their proprietary MDMA-assisted therapy for PTSD and the retraction of three articles on MDMA’s supposed efficacy. Perhaps because MDMA-assisted therapy isn’t a simple drug to be prescribed by psychiatrists.
127 
Let's personalize your content